TY  - GEN
AU  - Simon,Audrey
AU  - Peoch,Michel
AU  - Casassus,Philippe
AU  - Deconinck,Eric
AU  - Colombat,Philippe
AU  - Desablens,Bernard
AU  - Tournilhac,Olivier
AU  - Eghbali,Houchingue
AU  - Foussard,Charles
AU  - Jaubert,Jerome
AU  - Vilque,Jean Pierre
AU  - Rossi,Jean François
AU  - Lucas,Virginie
AU  - Delwail,Vincent
AU  - Thyss,Antoine
AU  - Maloisel,Frederic
AU  - Milpied,Noel
AU  - le Gouill,Steven
AU  - Lamy,Thierry
AU  - Gressin,Rémy
TI  - Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95
SN  - 1365-2141
PY  - 2010///1206
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - administration & dosage
KW  - Bleomycin
KW  - Cisplatin
KW  - Cyclophosphamide
KW  - Dacarbazine
KW  - Doxorubicin
KW  - Etoposide
KW  - Female
KW  - Humans
KW  - Ifosfamide
KW  - Lymphoma, T-Cell, Peripheral
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Prednisone
KW  - Survival Analysis
KW  - Treatment Outcome
KW  - Vinblastine
KW  - Vincristine
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1111/j.1365-2141.2010.08329.x
ER  -